Oncology
KL-6 is a serological marker for liver cancer in patients with hepatitis C
Published in Hepatitis Weekly, November 22nd, 2004
According to researchers in Japan, "we investigated the clinical significance of serum and intrahepatic KL-6/MUC1 (KL-6) in patients with hepatitis C virus (HCV) antibody-positive hepatocellular carcinoma (HCC). The subjects included 76 patients diagnosed with anti-HCV positive HCC, 69 with, and 51 without, liver cirrhosis (LC). Frozen serum samples were obtained from each subject to determine the serum KL-6 levels using an enzyme-linked immunosorbent assay."
"Expression of KL-6 antigen in the liver was also investigated using immunoperoxidase staining. The mean serum KL-6...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-11-22)
More Articles from Hepatitis Weekly
- Chronic Hepatitis B
Hepatitis B virus DNA in the liver correlates with extent of liver injury - Diagnostics
A new assay improves the timeliness and sensitivity of hepatitis C detection - Diagnostics
Core antigen assay can't confirm active hepatitis C virus infection - Epidemiology
The minimum spanning tree model tracks the source of hepatitis C outbreaks - Addiction Medicine
Injection drug users often develop hepatitis C virus superinfections - Business Update
Biotech applies for ASE listing, updates status of infectious diseases research - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
